Eliquis

Chemical Nameapixaban
Dosage FormTablet (oral; 2.5mg and 5mg)
Drug ClassInhibitors
SystemCardiovascular
CompanyBristol-Myers Squibb
Approval Year2012

Indication

  • Indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Last updated on 5/11/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Eliquis (apixaban) Prescribing Information2012Bristol-Myers Squibb Company, Princeton, New Jersey
Document TitleYearSource
Twice- or once-daily dosing of direct oral anticoagulants, a systematic review and meta-analysis. 2021Thrombosis Research
Efficacy and safety of non-vitamin K anticoagulants for atrial fibrillation in relation to different renal function levels: A network meta-analysis.2020Cardiovascular Therapeutics
Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis.2020Circulation: Cardiovascular Quality and Outcomes
Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: A systematic review and meta-analysis.2020Frontiers in Pharmacology
Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?—A systematic review.2020Stroke, Systemic or Venous Thromboembolism
Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: A network meta-analysis.2020Frontiers in Medicine
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.2020Medicine
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.2019Nephrology Dialysis Transplantation
A systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation.2019Clinical and Applied Thrombosis/Hemostasis
Elderly bleeding risk of direct oral anticoagulants in nonvalvular atrial fibrillation: A systematic review and meta‑analysis of cohort studies.2019Drugs in R&D
Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and high thromboembolic risk. A systematic review.2019Frontiers in Pharmacology
Non-vitamin K oral anticoagulants in nonvalvular atrial fibrillation: a network meta-analysis.2019Scandinavian Cardiovascular Journal
Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis.2019BMC Cardiovascular Disorders
Indirect comparison of novel oral anticoagulants among Asians with non-valvular atrial fibrillation in the real world setting: a network meta-analysis.2019BMC Cardiovascular Disorders
Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis.2019Cochrane Database of Systematic Reviews
A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants.2018International Journal of Cardiology
Interventions for preventing thromboembolic events in patients with atrial fibrillation: A systematic review.2018Annals of Internal Medicine
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.2018Cochrane Database of Systematic Reviews
A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants.2018Journal of Thrombosis and Haemostasis
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.2017The BMJ
Effectiveness and safety of non–vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: A systematic review and meta-analyses.2017Clinical Therapeutics
Effects of non–vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: A systematic review and meta-analysis.2017Journal of the American Heart Association
Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: A systematic review and meta-analysis.2017Stroke
Risk of gastrointestinal bleeding in patients taking non–vitamin K antagonist oral anticoagulants: A systematic review and meta-analysis.2017Clinical Gastroenterology and Hepatology
Comparative effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation: A systematic review and meta‑analysis of observational studies. 2016Drug Safety
Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.2016Clinical Pharmacology: Advances and Applications
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. 2016Expert Review of Pharmacoeconomics and Outcomes Research